As mentioned above, and discussed in more detail below, my own laboratory has combined the use of CD200:CD200R immunotherapy with cancer vaccines as an immunotherapeutic approach to blood cell malignancies and breast cancer in animal models, stimulating anti-tumor immunity with tumor antigens delivered in the form of whole cells [14,15]. This evidence concerns the gene CD200R1 and neoplasm.